FLI1 and invasive breast carcinoma: The role of FLI1 in immune regulation and its potential as an immune target have gradually been revealed; for instance, CXCL13, a chemokine for B cells and regulatory T cells, is upregulated by FLI1 deficiency in macrophages, potentially contributing to the development of tissue fibrosis, vasculopathy and immune activation in system sclerosis [16]; FLI1 haploinsufficiency increases the proportions of Th2- and Th17-like Tregs in bleomycin-induced profibrotic skin conditions [17]; FLI1 was further reported to be related to many immune cell types and immune system processes in BRCA [18].